Pfizer and biontech receive chmp positive opinion for their covid-19 vaccine

New york and mainz, germany, december 21, 2020 (globe newswire) — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) announced today that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) issued a positive opinion to recommend the conditional marketing authorization (cma) of the pfizer-biontech covid-19 vaccine (also known as bnt162b2), for active immunization to prevent covid-19 caused by sars-cov-2 virus, in individuals 16 years of age and older. the purpose of a cma is to allow for medicinal products to be authorized on a conditional basis for seriously debilitating or life-threatening diseases or for use in emergency situations in response to public health threats recognized either by the world health organization or the european union (eu).
BNTX Ratings Summary
BNTX Quant Ranking